Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $3.0 million.

  • Ovid Therapeutics' Accumulated Expenses fell 6110.16% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year decrease of 6110.16%. This contributed to the annual value of $6.0 million for FY2024, which is 812.39% down from last year.
  • Latest data reveals that Ovid Therapeutics reported Accumulated Expenses of $3.0 million as of Q3 2025, which was down 6110.16% from $2.9 million recorded in Q2 2025.
  • Ovid Therapeutics' 5-year Accumulated Expenses high stood at $13.2 million for Q1 2021, and its period low was $2.9 million during Q2 2025.
  • Moreover, its 5-year median value for Accumulated Expenses was $6.0 million (2025), whereas its average is $6.4 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 12038.06% in 2021, then tumbled by 6457.82% in 2025.
  • Over the past 5 years, Ovid Therapeutics' Accumulated Expenses (Quarter) stood at $7.7 million in 2021, then crashed by 41.28% to $4.5 million in 2022, then surged by 44.83% to $6.5 million in 2023, then dropped by 8.12% to $6.0 million in 2024, then tumbled by 50.63% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $2.9 million for Q2 2025, and $6.0 million during Q1 2025.